SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The S&P 500 ETF (SPY) is trending amid escalating Middle East tensions, fueled by Iranian strikes and reported damage to Saudi oil facilities, with the community sharply divided between anticipating a "bloodbath" or a "buy the dip" opportunity.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as an escalating Middle East conflict fuels intense debate among traders, with many bracing for significant market volatility and a potential downturn due to rising oil prices and put buying, while others anticipate a swift recovery, believing the geopolitical risks are already priced in.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Escalating geopolitical tensions in the Middle East, including US-Israel strikes on Iran and reported restrictions in the Strait of Hormuz, are driving intense interest in Indonesia Energy Corp Ltd (INDO). The community is actively discussing potential oil price surges, comparing the situation to past energy shocks, and anticipating a significant short squeeze for the low-float oil stock.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

BATL is trending as escalating Middle East tensions trigger a surge in oil prices, with the community actively discussing its significant short interest and the potential for a massive short squeeze as a primary driver.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending amid escalating geopolitical tensions in the Middle East, with community discussion sharply divided between concerns of a broader market sell-off and bullish anticipation for its newly announced AI inference chip and 6G infrastructure partnership. Many investors are weighing the immediate risk-off sentiment against the company's continued innovation and leadership in the AI sector.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Exxon Mobil is surging amid heightened geopolitical tensions in the Middle East, with reports of attacks on Saudi oil infrastructure and fears over the closure of the Strait of Hormuz fueling speculation of drastically higher crude prices and a "war trade" for energy stocks.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global (VG) is trending as escalating Middle East tensions, particularly concerning the Strait of Hormuz, fuel expectations of significant disruptions to global LNG supply. The community is actively discussing a "perfect storm" scenario where this, alongside upcoming Q4 earnings and substantial short interest, is poised to highlight VG's undervalued growth and spot market leverage in the energy sector.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas is a focal point for investors amid escalating global tensions, as its autonomous drone and counter-UAS technologies are seen as increasingly vital, sparking community speculation about significant contract wins and a potential short squeeze on its substantial short interest.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir (PLTR) is trending strongly as the community links its AI platforms to recent Middle East conflicts and precision strikes, buoyed by a bullish UBS upgrade and the perception that rival Anthropic's reported federal ban will further solidify Palantir's indispensable role in defense and intelligence AI.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is actively discussed following a significant public offering designed to fund its expansion in unmanned systems, hypersonics, and warfighter training solutions, coinciding with a series of recent contract wins. Community sentiment underscores the ongoing global demand for advanced drone and missile technologies, fueled by escalating geopolitical tensions and projected increases in defense spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Zen Downgrades Emergent Biosolutions (NYSE:EBS) to Buy

Wall Street Zen cut shares of Emergent Biosolutions from a "strong-buy" rating to a "buy" rating in a research report on Saturday...

Emergent Biosolutions Q4 Earnings Call Highlights

Emergent Biosolutions (NYSE:EBS) reported fourth-quarter and full-year 2025 results on a Feb. 26, 2026 earnings call, with management highlighting progress on its multi-year transformation plan...

<ul class="summary-bullets"><li>The company issues FY26 revenue guidance of $720 million-$760 million and Q1 guidance of $135 million-$155 million, both below consensus estimates.</li><li>Naloxone nasal spray revenues fell 41% due to rising competition, while anthrax biodefense product revenues rose 64% on delivery timing.</li><li>The company also announced new Canadian contracts worth up to C$140 million.</li></ul>Shares of Emergent BioSolutions, Inc. (EBS) fell over 20% in extended trading on Thursday after the company issued weaker-than-expected financial guidance for both the first quarter and full year 2026, overshadowing contract wins and a new stock buyback program.<a href="https://stocktwits.com/symbol/EBS">EBS stock</a> rose 0.8% in Thursday’s regular session.<h2 class="st-heading-2">Weak Outlook Weighs On Sentiment</h2>The biodefense company forecast full-year 2026 revenue in the range of $720 million to $760 million, below analysts’ consensus estimate of $809.4 million. The company also guided for first-quarter revenue of $135 million to $155 million, significantly below consensus expectations of $275 million.It also projected adjusted net income between $25 million and $45 million, and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $135 million to $155 million."Our team remains focused on long-term sustainable value and achieving our vision of enabling several durable and profitable verticals in the Company over time," said CEO Joe Papa.<h2 class="st-heading-2">Earnings Miss Adds Pressure</h2>The cautious outlook came alongside weaker quarterly performance. Emergent reported a fourth-quarter (Q4) loss of $0.43 per share, compared with earnings of $0.05 per share a year earlier. Revenue came in at $148.7 million, missing expectations of $217.5 million.Naloxone product revenues from its opioid overdose reversal nasal sprays declined 41% due to increased competition. Anthrax medical countermeasure revenues, which include vaccines and treatments used for biodefense preparedness, rose 64%, driven by the timing of delivery. "Emergent's 2025 results demonstrate significant progress executing our multi-year turnaround strategy, delivering improved operating margins, strong adjusted EBITDA of $205 million, increased cash flow and lower leverage," Papa said.<h2 class="st-heading-2">Positive Developments Fail To Offset Concerns</h2>The company also announced new agreements worth up to C$140 million with the Canadian government agencies to supply medical countermeasures for biological threat preparedness. Emergent expects to receive more than C$35 million in orders from these contracts this year.Separately, the board authorized a new $50 million share repurchase program running through March 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for EBS was ‘extremely bullish’ amid a 285% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ebs_ss_png_5927fdd04b.webp" alt="ebs ss.png" width="976" height="140"><figcaption>EBS sentiment and message volume as of February 27 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/ComradeKomisar/message/646069727">said</a>, “Pretty sure they 'sand bagged' the guidance, like they always do, and that order either will repeat, or we'll get it from Canada which can be threatned to lose the Winnipeg site, and move it to the US.”<stembedurl>https://stocktwits.com/ComradeKomisar/message/646069727</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Kawasaki1/message/646066600">said</a>, “Up 50 cents/ since the over reaction earlier...We were undervalued going into earnings and the future is still promising”<stembedurl>https://stocktwits.com/Kawasaki1/message/646066600</stembedurl>EBS stock has declined 10% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the Emergent BioSolutions logo of an US biopharmaceutical company is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today?

The board authorized a new $50 million share repurchase program running through March 2027.

Equity

Emergent Biosolutions (NYSE:EBS) Releases Quarterly Earnings Results

Emergent Biosolutions (NYSE:EBS - Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing...

Emergent Biosolutions (EBS) Expected to Announce Earnings on Monday

Emergent Biosolutions (NYSE:EBS) will be releasing its Q4 2025 earnings after the market closes on Monday, March 2. (View Earnings Report at...

Emergent Biosolutions Inc. $EBS Shares Purchased by Allianz Asset Management GmbH

Allianz Asset Management GmbH grew its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 149.0% during the 3rd quarter, according to the company in its most recent Form 13F...

New York State Common Retirement Fund Has $4.60 Million Stock Holdings in Emergent Biosolutions Inc. $EBS

New York State Common Retirement Fund lifted its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) by 32.6% in the third quarter, according to its most recent Form 13F filing...

Emergent Biosolutions (NYSE:EBS) Share Price Passes Above 200-Day Moving Average - Here's Why

Emergent Biosolutions (NYSE:EBS) Share Price Passes Above 200-Day Moving Average - Should You Sell...

<ul class="summary-bullets"><li>The Attorney General’s lawsuit alleges that Kramer knew about the manufacturing and contamination issues and yet executed a trading plan before those issues were made public in violation of the law.</li><li>James is now seeking damages, disgorgement, and costs from Kramer.</li><li>Emergent inked contracts worth $261 million with AstraZeneca in 2020 to manufacture the latter’s Covid-19 vaccine.</li></ul>Shares of Emergent Biosolutions Inc (EBS) slumped 13% on Thursday after New York State Attorney General Letitia James sued the company’s former CEO Robert G. Kramer for insider trading.James also inked a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ag.ny.gov/press-release/2026/attorney-general-james-sues-former-ceo-emergent-biosolutions-insider-trading">settlement</a> with Emergent under which the company will pay $900,000 in penalties for approving Kramer’s trading plan. Emergent will improve its executive trading policies, James said.<h2 class="st-heading-2">Transactions In Question</h2>Emergent inked contracts worth $261 million with AstraZeneca in 2020 to manufacture the latter’s Covid-19 vaccine. However, large amounts of the vaccines Emergent produced were contaminated, rendering them unusable.According to a probe by the Office of the Attorney General, Kramer was made aware of the contamination in October 2020 and the company omitted the unresolved contamination issues in communications through November. It instead approved Kramer’s trading plan under which he sold his company shares for over $10 billion, James said, while adding that Emergent's shares began to drop shortly after Kramer completed his sales in February 2021.The U.S. Food and Drug Administration (FDA) ordered a permanent halt to Emergent’s production of the AstraZeneca (AZN) vaccine in April 2021. The Attorney General’s lawsuit alleges that Kramer knew about the manufacturing and contamination issues and executed a trading plan before those issues were made public in violation of the law. James is now seeking damages, disgorgement, and costs from Kramer.“At the height of the COVID-19 pandemic, Robert Kramer illegally profited millions by selling his company shares, while knowing that Emergent faced issues producing the AstraZeneca vaccine for millions of people. Kramer’s actions were illegal and unethical, and we are holding him accountable,” James said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EBS rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user dismissed the penalty amount as irrelevant to the company’s financials.<stembedurl>https://www.stocktwits.com/KnuckleSandwich/message/641972166</stembedurl>Another termed the sell-off an “easy buying opportunity.”<stembedurl>https://www.stocktwits.com/AlarmedSheiky/message/641962084</stembedurl><a href="https://stocktwits.com/symbol/EBS">EBS stock</a> has gained 15% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-continues-rally-on-preliminary-revenue-numbers/cmU1wPAR4Jh">IBRX Stock Continues Rally — What’s Driving The Optimism Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The exterior view of the Emergent BioSolutions plant on April 01, 2021 in Baltimore, Maryland. (Photo by Tasos Katopodis/Getty Images)

Why Did EBS Stock Fall 13% Today?

New York State Attorney General Letitia James inked a settlement with Emergent under which the company will pay $900,000 in penalties. 

Emergent Biosolutions Stock Plummets Amid Insider Trading Allegations Against Former CEO

New York State Attorney General Letitia James inked a settlement with Emergent under which the company will pay $900,000 in penalties. 


Emergent Biosolutions (NYSE:EBS) Stock Price Down 7.4% - What's Next?

Emergent Biosolutions (NYSE:EBS) Stock Price Down 7.4% - Time to Sell...

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

EBS
Emergent Biosolutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EBS News

EBSEmergent Biosolutions Inc